

AMENDMENTS TO THE CLAIMS

1. (Previously Presented) A compound from 12 to 50 nucleobases in length targeted to a nucleic acid molecule encoding growth hormone receptor, wherein said compound comprises an at least 8 consecutive nucleobase portion of SEQ ID NO: 19; and wherein said compound is at least 95% complementary with SEQ ID NO: 4 as measured over the entirety of said compound.

2-3. (Canceled).

4. (Currently Amended) The compound according to claim 1 ~~comprising wherein~~ said compound is an oligonucleotide.

5. (Previously Presented) The compound according to claim 4 in which the oligonucleotide is a single-stranded oligonucleotide.

6. (Previously Presented) The compound according to claim 4 in which the oligonucleotide is a DNA oligonucleotide.

7. (Previously Presented) The compound according to claim 4 in which the oligonucleotide is a RNA oligonucleotide.

8. (Canceled).

9. (Currently Amended) The compound according to ~~claim 7~~ claim 1, wherein said compound is a short interfering RNA (siRNA) molecule.

10-12. (Canceled).

13. (Previously Presented) The compound according to claim 1 comprising 100% complementarity with SEQ ID NO: 4 as measured over the entirety of said compound.

14-19. (Canceled)

20. (Currently Amended) The compound according to claim 1 ~~further comprising wherein said compound comprises~~ at least one modified internucleoside linkage, modified nucleobase, modified sugar, or combination thereof.

21. (Previously Presented) The compound according to claim 20, wherein the modified sugar is selected from the group consisting of a 2'-O-(2-methoxyethyl), and a 4'-(CH₂)_n-O-2' bridge, wherein n is 1 or 2.

22. (Currently Amended) The compound according to claim 20 ~~comprising wherein~~ said compound comprises at least one phosphorothioate internucleoside linkage.

23. (Currently Amended) The compound according to claim 20 ~~comprising wherein~~
said compound comprises at least one 5-methylcytosine.

24-45. (Canceled)

46. (Currently Amended) The compound of claim 1, wherein said compound is an antisense oligonucleotide comprising the nucleobase sequence of SEQ ID NO: 19, ~~and further comprising wherein~~ said antisense oligonucleotide comprises a ten deoxynucleotide region flanked on both the 5' and the 3' ends with at least five 2'-O-(2-methoxyethyl) nucleotides, wherein each internucleoside linkage in said antisense oligonucleotide is a phosphorothioate and wherein each cytosine in said antisense oligonucleotide is a 5-methylcytosine.

47. (Previously Presented) A pharmaceutical composition comprising the antisense oligonucleotide of claim 46 and an ingredient selected from the group consisting of a pharmaceutically acceptable carrier, diluent, penetration enhancer, excipient and combinations thereof.

48-49. (Canceled).

50. (Previously Presented) A compound from 15 to 30 nucleobases in length targeted to a nucleic acid molecule encoding growth hormone receptor, wherein said compound comprises at least 8 consecutive nucleobases from SEQ ID NO: 19 and is at least 80% complementary with SEQ ID NO: 4 as measured over the entire length of said compound.

51. (Canceled).

52. (Previously Presented) The compound of claim 50 comprising at least one of a modified internucleoside linkage, a modified sugar, a modified nucleobase, or combination thereof.

53. (Previously Presented) The compound of claim 52 having at least one 2'-O-methoxyethyl sugar moiety.

54. (Previously Presented) The compound of claim 52 having at least one phosphorothioate internucleoside linkage.

55. (Previously Presented) The compound of claim 52 having at least one 5-methylcytosine.

56. (Previously Presented) The compound of claim 52 that is a pharmaceutically acceptable salt.

57. (Previously Presented) The compound of claim 50 that is a pharmaceutically acceptable salt.

58. (Previously Presented) The compound of claim 50, wherein said compound is at least 95% complimentary to SEQ ID NO: 4 as measured over the entire length of said compound.

59. (Previously Presented) The compound of claim 50, wherein said compound is 100% complimentary to SEQ ID NO: 4 as measured over the entire length of said compound.

60. (Previously Presented) The compound of claim 46, wherein said compound is 20 nucleotides in length.

61. (Previously Presented) The compound of claim 50, wherein said compound is at least 90% complementary with SEQ ID NO: 4 as measured over the entire length of said compound.

62. (Previously Presented) The compound of claim 50, wherein said compound comprises the nucleic acid sequence of SEQ ID NO: 19.

63-65. (Canceled).

66. (Previously Presented) The compound of claim 59, wherein said compound is an oligonucleotide.

67. (Previously Presented) The compound of claim 66, comprising at least one 2'-O-(2-methoxyethyl) nucleotide, at least one phosphorothioate internucleoside linkage, and at least one 5-methylcytosine.

68. (Currently Amended) The compound of claim 67, ~~further comprising wherein~~ said compound comprises:

a region of deoxynucleotides flanked on both the 5' and the 3' ends of said region with at least one 2'-O-(2-methoxyethyl) nucleotide;

wherein each internucleoside linkages of said compound is a phosphorothioate internucleoside linkage;

and wherein each cytosine of said compound is a 5-methylcytosine.

69. (Previously Presented) The compound of claim 68, wherein said compound comprises the nucleic acid sequence of SEQ ID NO:19.

70. (Currently Amended) A compound comprising a modified oligonucleotide consisting of 20 linked nucleosides and having a nucleobase sequence consisting of the

nucleobase sequence recited in SEQ ID NO: 19, ~~and further comprising wherein said modified oligonucleotide consists of~~ a ten deoxynucleotide region flanked on both the 5' and the 3' ends with five 2'-O-(2-methoxyethyl) nucleotides, wherein each internucleoside linkage in said modified oligonucleotide is a phosphorothioate and each cytosine in said modified oligonucleotide is a 5-methylcytosine.

71. (Previously Presented) A composition comprising the compound of claim 70 or a salt thereof and a pharmaceutically acceptable carrier or diluent.

72. (Previously Presented) The composition of claim 71, wherein the salt is a sodium salt.

73. (Currently Amended) The compound of claim 1, ~~further comprising wherein said compound comprises:~~

a region of deoxynucleotides flanked on both the 5' and the 3' ends of said region with at least one 2'-O-(2-methoxyethyl) nucleotide;

wherein each internucleoside linkage[[s]] of said compound is a phosphorothioate internucleoside linkage;

and wherein each cytosine of said compound is a 5-methylcytosine.